Why Is Pancreatic Cancer Called the "King of Cancers"?
Pancreatic cancer has earned the grim title of "癌中之王" (King of Cancers) for a reason: it is one of the deadliest malignancies known to medicine. Despite decades of research and significant advances in cancer treatment, the five-year survival rate for pancreatic cancer remains below 12% globally — and for patients diagnosed with metastatic disease, it falls to just 3%. Understanding why this cancer is so lethal is the first step toward protecting yourself.
Five Reasons Pancreatic Cancer Is So Deadly
1. Silent Progression: No Early Symptoms
The pancreas is a deep retroperitoneal organ — tucked behind the stomach, in front of the spine, surrounded by major blood vessels and other organs. This anatomical location means that a growing tumor causes no pain, no visible lump, and no obvious symptoms until it has grown large enough to compress or invade surrounding structures.
By the time most patients develop symptoms — jaundice (yellowing of the skin and eyes), back pain, unexplained weight loss, new-onset diabetes, or digestive problems — the cancer has typically already spread beyond the pancreas. Approximately 80–85% of pancreatic cancers are diagnosed at an advanced or metastatic stage, when curative surgery is no longer possible.
This is in stark contrast to cancers like breast, colorectal, or cervical cancer, where effective screening programs can detect disease at early, curable stages.
2. Aggressive Biology and Rapid Progression
Pancreatic ductal adenocarcinoma (PDAC) — which accounts for approximately 90% of pancreatic cancers — is biologically one of the most aggressive cancers. Key features include:
- Dense stromal microenvironment (desmoplasia): Pancreatic tumors are surrounded by a thick, fibrous stroma that acts as a physical barrier, preventing chemotherapy drugs from reaching tumor cells and suppressing immune cell infiltration
- Early metastasis: Pancreatic cancer cells disseminate to the liver, lungs, and peritoneum very early in the disease course — often before the primary tumor is detectable on imaging
- Rapid doubling time: PDAC grows and spreads faster than most other solid tumors
- Genetic complexity: PDAC is driven by mutations in KRAS (present in >90% of cases), TP53, SMAD4, and CDKN2A — a combination that makes it highly resistant to most targeted therapies
3. Resistance to Treatment
Pancreatic cancer is notoriously resistant to most cancer treatments:
- Chemotherapy: Response rates are low. The most effective regimens — FOLFIRINOX and gemcitabine/nab-paclitaxel — extend median survival in metastatic disease by months, not years
- Targeted therapy: Unlike lung cancer or breast cancer, PDAC has very few actionable mutations. The exception is the ~1–2% of patients with BRCA1/2 mutations, who may benefit from PARP inhibitors
- Immunotherapy: Checkpoint inhibitors (PD-1/PD-L1 inhibitors) that have transformed treatment of many cancers are largely ineffective in PDAC, due to the immunosuppressive tumor microenvironment and low tumor mutational burden
- Radiation: Has a limited role in PDAC; used primarily for locally advanced disease or pain palliation
4. Surgery Is the Only Cure — But Most Patients Are Ineligible
Surgical resection (Whipple procedure / pancreaticoduodenectomy for head tumors; distal pancreatectomy for body/tail tumors) is the only potentially curative treatment for pancreatic cancer. However:
- Only 15–20% of patients have resectable disease at diagnosis
- Even after successful resection, the 5-year survival rate is only 20–25% — because microscopic metastases are often already present
- Pancreatic surgery is among the most complex and high-risk operations in abdominal surgery, requiring highly experienced surgical teams at high-volume centers
5. No Established Population-Wide Screening Program
Unlike colorectal cancer (colonoscopy), breast cancer (mammography), or cervical cancer (Pap smear), there is currently no validated, cost-effective screening test for pancreatic cancer in the general population. This is because:
- The incidence of pancreatic cancer in the general population is relatively low (~13 per 100,000), making population-wide screening inefficient
- Available tests (CA 19-9 blood marker, CT scan, MRI, endoscopic ultrasound) lack sufficient sensitivity and specificity for early detection in average-risk individuals
- CA 19-9, the most commonly used tumor marker, is elevated in only 70–80% of pancreatic cancers — and can be elevated in benign conditions (pancreatitis, biliary obstruction, liver disease)
This means that by the time a pancreatic cancer is found incidentally or through symptom investigation, it is usually already advanced.
Warning Signs: When to Seek Urgent Evaluation
While early pancreatic cancer is usually asymptomatic, certain symptoms should prompt immediate medical evaluation:
- Painless jaundice (yellowing of skin and eyes, dark urine, pale stools) — caused by bile duct obstruction by a tumor in the head of the pancreas; this is actually one of the "earlier" presentations and should be investigated urgently
- New-onset diabetes in adults over 50 with no obvious risk factors — pancreatic cancer can destroy insulin-producing cells or cause insulin resistance; new diabetes may precede cancer diagnosis by 1–2 years
- Unexplained weight loss — particularly rapid, unintentional weight loss of >5% body weight
- Upper abdominal or back pain — dull, persistent pain radiating to the back, often worse when lying flat and relieved by leaning forward
- Unexplained acute pancreatitis — particularly in non-drinkers without gallstones; a tumor can obstruct the pancreatic duct and cause pancreatitis
- New or worsening digestive symptoms — nausea, loss of appetite, fatty stools (steatorrhea) from exocrine pancreatic insufficiency
- Migratory thrombophlebitis (Trousseau's sign) — recurrent blood clots in unusual locations; a paraneoplastic manifestation of pancreatic cancer
Who Is at High Risk? Risk Factors for Pancreatic Cancer
While most pancreatic cancers occur in people without identifiable risk factors, certain conditions significantly increase risk:
Non-Modifiable Risk Factors:
- Age: Risk increases sharply after age 50; median age at diagnosis is 71
- Family history: Having one first-degree relative with pancreatic cancer doubles the risk; two or more first-degree relatives increases risk 6–2fold
-
Hereditary syndromes:
- BRCA1/2 mutations (hereditary breast-ovarian cancer syndrome): 2–6x increased risk
- PALB2 mutations: ~2–3x increased risk
- Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations): ~8x increased risk
- Familial atypical multiple mole melanoma (FAMMM / CDKN2A mutations): ~13–22x increased risk
- Peutz-Jeghers syndrome (STK11 mutations): ~130x increased risk
- Hereditary pancreatitis (PRSS1 mutations): ~50x increased risk
- Chronic pancreatitis: Long-standing inflammation of the pancreas increases risk ~13–16x; hereditary pancreatitis carries even higher risk
- New-onset diabetes over age 50 (as noted above)
- Intraductal papillary mucinous neoplasms (IPMNs): Precancerous cystic lesions of the pancreas that require surveillance
Modifiable Risk Factors:
- Smoking: The strongest modifiable risk factor; smokers have 2–3x the risk of non-smokers; accounts for approximately 25% of pancreatic cancers
- Obesity and physical inactivity: BMI > 30 increases risk ~1.5x; abdominal obesity is particularly associated
- Heavy alcohol consumption: Increases risk through chronic pancreatitis
- Long-standing type 2 diabetes: ~2x increased risk (though the relationship is complex — diabetes may be both a risk factor and an early manifestation)
- Diet: High consumption of red and processed meat; low consumption of fruits and vegetables
How Often Should You Be Screened? Screening Recommendations by Risk Group
Because population-wide screening is not currently recommended, screening guidelines focus on high-risk individuals who have a meaningful enough lifetime risk to justify the cost, inconvenience, and potential harms of surveillance.
Average Risk (General Population)
Recommendation: No routine pancreatic cancer screening.
For people without risk factors, the lifetime risk of pancreatic cancer is approximately 1.6% — too low to justify routine screening with current tools. Focus instead on modifiable risk factor reduction: quit smoking, maintain healthy weight, limit alcohol, manage diabetes.
Elevated Risk: New-Onset Diabetes Over Age 50
Recommendation: Discuss with your physician; consider CA 19-9 + abdominal imaging at diagnosis.
New-onset diabetes in adults over 50 without obvious risk factors (obesity, family history of T2D) should prompt consideration of pancreatic evaluation, particularly if accompanied by weight loss. A baseline CT or MRI of the abdomen and CA 19-9 level is reasonable. If normal, repeat evaluation is guided by symptoms.
High Risk: One First-Degree Relative with Pancreatic Cancer
Recommendation: Consider surveillance starting at age 50, or 10 years before the youngest affected relative's age at diagnosis.
Preferred modality: Endoscopic ultrasound (EUS) or MRI/MRCP, alternating annually. EUS is the most sensitive imaging modality for detecting small pancreatic lesions and is available at leading centers in Shanghai.
Very High Risk: Hereditary Syndromes or ≥2 Affected First-Degree Relatives
Recommendation: Formal surveillance program starting at age 40–50 (or 10 years before youngest affected relative), with annual EUS and/or MRI/MRCP.
International guidelines (CAPS Consortium, ISGP) recommend enrollment in a formal surveillance program at a high-volume center for individuals with:
- ≥2 first-degree relatives with pancreatic cancer
- BRCA2, PALB2, ATM, CDKN2A, STK11, or PRSS1 mutations with a family history of pancreatic cancer
- Lynch syndrome with a family history of pancreatic cancer
- Peutz-Jeghers syndrome (regardless of family history)
- Hereditary pancreatitis
Surveillance protocol: Annual alternating EUS and MRI/MRCP; CA 19-9 at each visit; genetic counseling and testing for all first-degree relatives.
Pancreatic Cysts (IPMNs and Other Cystic Lesions)
Recommendation: Surveillance frequency determined by cyst size, features, and guidelines (AGA, European, Fukuoka).
Pancreatic cysts are increasingly detected incidentally on CT and MRI scans performed for other reasons. Most are benign, but some — particularly IPMNs — have malignant potential. Surveillance intervals range from every 6 months (for high-risk features) to every 2–3 years (for small, low-risk cysts), guided by international consensus guidelines.
Screening Tools: What Tests Are Used?
- Endoscopic Ultrasound (EUS): The gold standard for pancreatic surveillance in high-risk individuals; provides high-resolution imaging of the pancreas without radiation; can detect lesions as small as 2–5 mm; allows fine-needle aspiration (FNA) biopsy of suspicious lesions
- MRI / MRCP (Magnetic Resonance Cholangiopancreatography): Excellent for detecting cystic lesions and ductal abnormalities; no radiation; preferred for patients who cannot tolerate endoscopy
- CT scan (pancreatic protocol): Good for staging known cancer; less sensitive than EUS for small lesions; involves radiation
- CA 19-9: Blood tumor marker; useful for monitoring known disease and post-surgical surveillance; not reliable for early detection (low sensitivity and specificity)
- Liquid biopsy / ctDNA: Emerging technology; circulating tumor DNA in blood may enable earlier detection; not yet validated for clinical screening
Why Seek Pancreatic Cancer Evaluation in Shanghai?
Shanghai's leading academic medical centers offer world-class expertise in pancreatic cancer diagnosis, surveillance, and treatment:
- High-volume pancreatic surgery: Ruijin Hospital has one of China's leading pancreatic surgery programs, with experienced surgeons performing high volumes of Whipple procedures and minimally invasive pancreatectomies
- Advanced endoscopy: EUS with FNA for pancreatic lesion evaluation and ERCP for biliary decompression are available at multiple centers in Shanghai
- Multidisciplinary tumor boards: Pancreatic cancer cases are reviewed by teams including surgery, oncology, radiology, and pathology to ensure optimal treatment planning
- Access to clinical trials: Shanghai's academic centers participate in international trials of novel pancreatic cancer therapies
- Genetic counseling: For patients with hereditary risk, genetic counseling and comprehensive panel testing are available
For patients with gastrointestinal cancers or liver cancer, Shanghai also offers integrated multidisciplinary care across related cancer types.
What to Expect: Your Care Journey with CMCS
China Medical Concierge Shanghai (CMCS) coordinates specialist consultations for pancreatic cancer evaluation, surveillance, and treatment:
- Pre-arrival review: We review your imaging, laboratory results, family history, and genetic testing results to identify the most appropriate specialist and investigation pathway
- Specialist matching: We connect you with the right gastroenterologist (for EUS surveillance), pancreatic surgeon (for resectable disease), or oncologist (for advanced disease)
- Appointment and investigation coordination: We schedule EUS, MRI, CT, and laboratory investigations efficiently, minimizing your time in Shanghai
- Interpretation and translation: Our bilingual coordinators accompany you to all appointments
- Comprehensive report: You receive a clear summary of findings and recommendations in English for your home physicians
To discuss your case or request a consultation, contact us:
0 Kommentare